logo
Early detection of ‘bubble boy disease' helps save lives of newborns

Early detection of ‘bubble boy disease' helps save lives of newborns

Straits Times09-06-2025
Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). ST PHOTO: NG SOR LUAN
Medical Mysteries Early detection of 'bubble boy disease' helps save lives of newborns Medical Mysteries is a series that spotlights rare diseases or unusual conditions.
SINGAPORE – Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID).
This meant that he was born without a functioning immune system, making him highly vulnerable to even the common flu. Without treatment, Mannat would not have made it past his first birthday.
His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt 'because I made him this way'.
SCID is a rare life-threatening genetic disorder that affects one in 50,000 babies worldwide, with one new case born in Singapore every two years.
'It did not help our state of mind when his odds were stacked against him,' said her husband Harminder Singh, 39, an IT consultant.
It is also known as the 'bubble boy disease' after David Vetter, an American boy with the disease who captured the world's attention for living all his life in a sterile plastic enclosure – his 'bubble'.
At the time of his birth in 1971, a bone marrow transplant from an exact matched donor was the only cure for SCID, but there was no match available in David's family.
In 1984, four months after receiving a bone marrow transfusion via a new technique, the 12-year-old died from lymphoma, a cancer later traced to a dormant Epstein-Barr virus in the donor bone marrow.
As for baby Mannat, he had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done.
Mannat Singh was born without a functioning immune system, making him highly vulnerable to even the common flu.
ST PHOTO: NG SOR LUAN
Memories of what the couple went through with their younger son brought back tears to Mr Singh, who said: 'We were prepared to do whatever we could to give Mannat the best chance at life. We took a step at a time, discussing putting him on chemotherapy and deferring to the experts.'
Fortunately for Mannat, his condition was picked up at the KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (Nens) programme.
The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis.
In 2024, all newborns at KKH were screened under Nens, while the national screening rate in Singapore is 96 per cent. This involves pricking the baby's heels to collect a blood sample between 24 and 72 hours after birth.
Screening for SCID involves checking the baby's bloody for DNA fragments called T-cell receptor excision circles (Trecs), which show that the immune system is making T-cells properly, said geneticist from KKH Ting Teck Wah.
The test does not confirm an SCID diagnosis, but abnormalities such as low or absent Trecs signals that the baby needs to go through more testing, he said.
After screening almost 178,000 babies since 2019, Nens has picked up two babies positive for SCID, Dr Ting added.
Dr Bianca Chan, a consultant with the rheumatology and immunology services at KKH, said the only real curative treatment for SCID is a bone marrow transplant from a healthy donor. Stem cells from the bone marrow from a health donor can develop into infection-fighting T-cells, helping babies with SCID build a functioning immune system.
'The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection,' she said.
Dr Chan added that if the baby has an active infection before the transplant, its survival rate even with transplant is only 50 per cent 'because it becomes very, very difficult to have a successful transplant'.
Mannat Singh and parents Harminder Kaur and Harminder Singh, with KKH doctors (back row, from left) Dr Michaela Seng, Dr Ting Teck Wah and Dr Bianca Chan.
ST PHOTO: NG SOR LUAN
Dr Michaela Seng, a senior consultant with the haematology and oncology service at the hospital, said a programme is immediately put in place to protect the child from infections before doctors prepare for donor selection.
'We meet the parent to explain the implications of the diagnosis and tell them they are typically appropriately suitable as potential donors. We also go through the process of harvesting and processing the donor stem cells, how the lab then receives these stem cells ... and prepare small bags of what we call memory T-cells that help fight infection,' she said.
'During this time, the baby, is admitted to the transplant unit and undergoes complete isolation. For seven days, he is given conditioning therapy, which is chemotherapy that is tailored to the size and the weight of the baby to allow us to clear unnecessary cells that would prevent successful engraftment of the donor stem cells. The donor cells are then infused, and we wait for the transplant to take effect,' she added.
Mannat became the first newborn in Singapore to have his SCID diagnosed at birth and the first to receive a stem cell transplant – from his mother's bone marrow – before the symptoms emerge.
Today, at 19 months, Mannat is healthy and asserting himself with his parents and older brother Birakaal, aged four.
'I feel now that life has returned to normal and we have put the past behind us. We are now looking forward to having the boys grow up healthy and happy,' Ms Kaur said.
Join ST's WhatsApp Channel and get the latest news and must-reads.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary

International Business Times

time3 hours ago

  • International Business Times

Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary

US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.

Trump pressures 17 pharma CEOs to cut US drug prices
Trump pressures 17 pharma CEOs to cut US drug prices

Business Times

time19 hours ago

  • Business Times

Trump pressures 17 pharma CEOs to cut US drug prices

[WASHINGTON] President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash US prescription drug prices to match those paid overseas, the White House said on Thursday. Trump signed a sweeping executive order in May demanding drugmakers cut US medicine prices to match those abroad, saying that if companies did not comply, the government could use rulemaking to bring prices down or pursue other measures, such as importing cheaper medicines from overseas. Trump sent the letters to the chief executives of Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson and AstraZeneca, among others, the White House said. 'Most proposals my Administration has received to 'resolve' this critical issue promised more of the same; shifting blame and requesting policy changes that would result in billions of dollars in handouts to industry,' Trump wrote in the letters, copies of which were posted on his Truth Social account. Shares of Pfizer, Eli Lilly and Gilead Sciences closed down about 2 per cent each, while the NYSE Arca Pharmaceutical Index fell 3 per cent on Thursday. Trump called on drugmakers to provide so-called most-favoured-nation prices to every patient enrolled in the government Medicaid health programme for low-income people, and to guarantee such pricing for new drugs. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up The policy is aimed at cutting US prescription drug prices to the lowest possible price paid by members of the Organisation for Economic Co-operation and Development, which includes most of the world's largest economies. Trump also said companies must return excess overseas revenue from raising prices in other countries to offset lower prices in the US to American patients and taxpayers through an agreement with the government. He is requiring drugmakers to stipulate they would not offer other developed nations better prices than what they offer the United States, and said his administration would provide ways to cut out middlemen and sell directly to patients, provided they do so at most-favoured-nation prices. Trump gave companies until Sept 29 to respond with binding commitments to those terms. 'If you refuse to step up, we will deploy every tool in our arsenal to protect Americans from abusive drug pricing practices,' he warned. Analysts, lobbyists and drug pricing experts said it seemed unlikely that the pharmaceutical companies would comply with Trump's demand to lower US prices. 'I might expect them to try to determine if any of their current products might be made available via direct sales (one of the requests) at a lower price than currently available in the US,' said Stacie Dusetzina, professor of health policy at Nashville's Vanderbilt University. UBS analyst Trung Huynh said Trump's letters were a repeat of earlier demands and played down any likely industry impact, calling it 'just another shot in the dark.' Trump has already pushed for voluntary changes and some companies have pledged to build new US manufacturing plants. US patients pay by far the most for prescription medicines, often nearly three times more than in other developed nations. The country also invests heavily in pharmaceutical research and development. Drugmakers have said drastic price cuts would stifle innovation. Pharmaceutical companies including Pfizer, Novartis, AbbVie and German Merck KGaA's US division, EMD Serono, said they were open to working with the Trump administration. Pfizer is working closely with the Trump Administration and Congress to improve access and affordability for American patients, said spokeswoman Amy Rose. 'Our discussions have been productive,' she said. REUTERS

Trump pressures 17 pharma CEOs to cut US drug prices
Trump pressures 17 pharma CEOs to cut US drug prices

Straits Times

timea day ago

  • Straits Times

Trump pressures 17 pharma CEOs to cut US drug prices

Sign up now: Get ST's newsletters delivered to your inbox US President Donald Trump has sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans. WASHINGTON - US President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on July 31. Letters were sent to top executives at Eli Lilly, Sanofi, Regeneron, Merck & Co, Johnson & Johnson, and AstraZeneca, among others. Copies of the letters were posted on Mr Trump's Truth Social account. The president is calling on the companies to extend most favoured nation pricing to Medicaid, guarantee such pricing for new drugs, and return excess overseas revenue to American patients and taxpayers, without providing details. Mr Trump has given the companies until Sept 29 to respond with binding commitments to those terms. 'According to recent data, the prices that Americans have been paying for brand name drugs are more than three times the price other similarly developed nations pay,' said White House press secretary Karoline Leavitt. She added the administration will 'deploy every tool in our arsenal' to end 'abusive drug pricing practices.' REUTERS White House press secretary Karoline Leavitt holding up a letter from US President Donald Trump to Mr David Ricks, Eli Lilly's CEO, during a media briefing on July 31. PHOTO: NYTIMES

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store